Translation has undoubtedly become a key facet of scientific research in recent years. Engineering research has led to numerous scientific discoveries that have the potential to transform clinical medicine. However, converting these discoveries into actual useful clinical technologies is a major challenge. Several factors determine the likelihood of success of such translation including safety, manufacturability, regulatory hurdles, cost, and patient acceptance. These issues are not typically considered in fundamental academic research, yet they are increasingly becoming a key part of the DNA of academic research. Clinical translation also often requires concurrent commercial translation, which brings its own challenges and constraints. 1 As we collectively advance our research and seek to increase its societal impact, these translational considerations must be catered to and adequately addressed. BioTM is a forum for discussing these issues and publishing manuscripts that provide new insights into understanding and overcoming these issues. Toward this goal, we have published several articles that provide a critical assessment of success and challenges in some of the key areas of interest including nanomedicine, 2 gene therapy 3 responsive materials and biotechnology. 4, 5 In terms of scientific topics, BioTM has focused on subjects where Engineering, Chemical Engineering in particular, has made a strong fundamental and translational impact on the field. These topics include drug delivery, 6-10 Nucleic acid delivery, 3, [11] [12] [13] [14] Regenerative Medicine, [15] [16] [17] Biotechnology, 4, 18 Nanomedicine, [19] [20] [21] [22] [23] Biomedical Devices, 24 and immunotherapy. 25, 26 We look forward to continue building our strengths in these fields and expand the list to include additional key areas.
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As we start our fifth year, I look forward to many more exciting developments. BioTM was recently selected for coverage in Clarivate Analytics and is now fully indexed in Web of Science, in addition to full indexing in Pub Med Central (PMC). The journal is now scheduled
